Codeine

What the laboratory says this test is for

Monitoring of parent compounds and their metabolites in urine. The results of this test are used in specific treatment programs to determine compliance with prescribed dosing schedules.

What the laboratory says this test is for

Detection of in utero exposure to drugs of abuse consistent with maternal use during the second and third trimesters of pregnancy; Newborn (neonatal) toxicology.

What the laboratory says this test is for

Detection of in utero exposure to drugs of abuse consistent with maternal use during the second and third trimesters of pregnancy; Newborn (neonatal) toxicology.

What the laboratory says this test is for

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

What the laboratory says this test is for

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

What the laboratory says this test is for

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

What the laboratory says this test is for

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

What the laboratory says this test is for

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

What the laboratory says this test is for

This definitive drug assay is used to confirm in utero opioid exposure and identify the specific opioid(s) with gas chromatography/mass spectrometry [1]. Opioids included in this panel are codeine, morphine, hydrocodone, hydromorphone, and oxycodone. This test does not detect fentanyl, a major contributor to fatal overdoses in the United States [2].Meconium begins to form around 12 weeks' gestation and accumulates mostly during the last trimester. Opioids used by mothers, and opioid metabolites, may deposit in meconium by diffusing across placentas or fetuses swallowing amniotic fluid. Adverse effects of in utero opioid exposure include preterm birth, low birthweight, birth defects, and neonatal opioid withdrawal syndrome. The clinical presentation of neonates varies by opioid type, maternal drug history, and other factors. Maternal self-reporting of opioid intake may be unreliable. Therefore, confirming opioid exposure via meconium testing can provide information necessary for clinical management of affected neonates [1,3,4].The American Academy of Pediatrics recommends that meconium, urine, and umbilical cord tissue should all be considered for opioid testing. However, neonatal urine reflects only recent opioid exposure; umbilical cord tissue, though easy to collect, is not well understood as a specimen for opioid testing. For mothers who receive frequent toxicology testing to monitor treatment of opioid use disorder, meconium or umbilical cord tissue opioid testing does not provide additional clinical information and may not be necessary [4].Results equal to or greater than the cutoff value for each opioid are reported as quantitative values and indicate in utero exposure; results less than cutoff are reported as negative. Because the frequency of drug use during pregnancy may affect detection of drugs in meconium, negative results do rule out in utero exposure to opioids [1].The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.⁠⁠⁠⁠⁠⁠⁠References1. Langman LJ, et al, eds. Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients. American Association for Clinical Chemistry; 2018. Accessed October 1, 2021. https://www.aacc.org/-/media/Files/Science-and-Practice/Practice-Guidelines/Pain-Management/LMPGPain-Management20171220.pdf?la=en&hash=19670524407619F78999AB60731A24CB4901939D2. Wilson N, et al. MMWR Morb Mortal Wkly Rep. 2020;69(11):290-297.3. About opioid use during pregnancy. Centers for Disease Control and Prevention. Accessed November 2, 2021. https://www.cdc.gov/pregnancy/opioids/basics.html4. Patrick SW, et al; Committee on Fetus and Newborn; Committee on Substance Use and Prevention. Pediatrics. 2020;146(5).

What the laboratory says this test is for

This panel is useful for confirmation of screen positive results.

What the laboratory says this test is for

Detection of in utero exposure to drugs of abuse consistent with maternal use during the second and third trimesters of pregnancy; Newborn (neonatal) toxicology.

What the laboratory says this test is for

Opiates possess exceptional analgesic properties and have become the mainstay of pain management therapies. Being both psychologically and physically addictive, the monitoring of opiate use and abuse is a major component of any treatment program. The test is a definitive assay using liquid chromatography mass spectroscopy (LC/MS/MS) methodology. Therapeutic urine drug monitoring of the opiates is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

What the laboratory says this test is for

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

What the laboratory says this test is for

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

What the laboratory says this test is for

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

What the laboratory says this test is for

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

What the laboratory says this test is for

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.